SpringerLink
Log in

Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors

  • Original Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

The standard renoprotection is based on the inhibition of the renin-angiotensin system (RAS) by angiotensin convertase inhibitors (ACEi) or angiotensin II receptor 1 blockers (AT1B). The aim of our study was to analyze the effects of the addition of AT1B to ACEi-based renoprotection in children with chronic kidney disease. We examined 11 children with a mean age of 10.5 years (range, 0.5–18 years) with a mean glomerular filtration rate (GFR) of 61±61 ml/min/1.73 m2. In four patients, the primary renal disease was hemolytic uremic syndrome, in three congenital nephrotic syndrome (CNS), in two reflux nephropathy, prune-belly syndrome in one and acute cortical necrosis in one. All patients were treated with complex hypotensive ACEi-based therapy. AT1B losartan was added in a mean dose of 0.9 mg/kg/day. The change in GFR, proteinuria and blood pressure at two 12-month intervals before and after adding AT1B was compared. The results showed that during the 12 months preceding AT1B therapy, there was no change in blood pressure and proteinuria, but the GFR declined in 7 of 11 patients. After the 12th month of add-on therapy with AT1B, there was a significant decrease in both absolute and indexed blood pressure values. Proteinuria decreased in eight patients, did not change in one and increased in two, including one with CNS. The GFR stabilized or increased in eight patients and decreased in three patients with CNS. In 7 of 11 patients, there was a significant, but not threatening increase in serum potassium. In conclusion, add-on renoprotection with AT1B added to ACEi is safe and significantly improves the renoprotective effects of ACEi treatment in children with progressive nephropathies, including patients with advanced CKD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Del Vecchio L, Locatelli F (2001) The renoprotective effect of combined antihypertensive drugs. J Nephrol 14:7–14

    PubMed  Google Scholar 

  2. Lama G, Salsano ME, Pedulla’ M, Grassia C, Ruocco G (1997) Angiotensin converting enzyme inhibitors and reflux nephropathy: a 2-year follow-up. Pediatr Nephrol 11:714–718

    Article  CAS  Google Scholar 

  3. Trachtman H, Gauthier B (1988) Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal disease. J Pediatr 112:295–298

    Article  CAS  Google Scholar 

  4. Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF (2000) Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 18:89–95

    CAS  Google Scholar 

  5. Nakao N, Seno H, Kasuga H, Toriyama T, Kawahara H, Fukagawa M (2004) Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: a COOPERATE-ABP substudy. Am J Nephrol 24:543–548

    Article  CAS  Google Scholar 

  6. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T (2003) Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361:117–124

    Article  CAS  Google Scholar 

  7. Shiigai T, Schichiri M (2001) Late escape from the antiproteinuric effect of ACE inhibitors in nondiabetic renal disease. Am J Kid Dis 37:477–483

    Article  CAS  Google Scholar 

  8. Kincaid-Smith P, Fairley KF, Packham D (2004) Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure. Nephrol Dial Transplant 19:2272–2274

    Article  CAS  Google Scholar 

  9. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The fourth report on the diagnosis, evaluation and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576

    Article  Google Scholar 

  10. Wuhl E, Mehls O, Schaefer F; ESCAPE Trial Group (2004) Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. Kidney Int 66:768–776

    Article  Google Scholar 

  11. Van Dyck M, Proesmans W (2004) Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome. Pediatr Nephrol 19:688–690

    Article  Google Scholar 

  12. Litwin M (2004) Risk factors for renal failure in children with non-glomerular nephropathies. Pediatr Nephrol 19:178–186

    Article  Google Scholar 

  13. Adler L, Mathew R, Futterweit S, Frank R, Gauthier BG, Kashtan CE, Trachtman H (2002) Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-beta and nitrite excretion. BMC Nephrol 3:2

    Article  Google Scholar 

  14. Holmberg C, Trygvasson K, Kestila MK, Jalanko HJ (2004) Congenital nephrotic syndrome. In: Avner ED, Harmon WE, Niaudet P (eds) Pediatric nephrology, 5th edn. Lippincot Wiliams & Wilkins, pp 503–516

  15. Hamed RM, Shomaf M (2002) Congenital nephritic syndrome: a clinico-pathological study of 30 children. J Nephrol 14:104–109

    Google Scholar 

  16. Ellis D, Moritz ML, Vats A, Janosky JE (2004) Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders. Am J Hypertens 17:928–935

    CAS  PubMed  Google Scholar 

  17. Gartenmann AC, Fossali E, von Vigier RO, Simonetti GD, Schmidtko J, Edefonti A, Bianchetti MG (2003) Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood. Kidney Int 64:1450–1454

    Article  CAS  Google Scholar 

  18. Tanaka H, Suzuki K, Nakahata T, Tsugawa K, Konno Y, Tsuruga K, Ito E, Waga S (2004) Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy. Pediatr Int 46:576–579

    Article  CAS  Google Scholar 

  19. Yang Y, Ohta K, Shimizu M, Nakai A, Kasahara Y, Yachie A, Koizumi S (2005) Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy. Clin Nephrol 64:35–40

    Article  CAS  Google Scholar 

  20. Ihle BU, Whitwirth JA, Shahinfar S, Cnaan A, Kincaid-Smith PS, Becker GJ (1996) Angiotensin-converting enzyme inhibition in non-diabetic progressive renal insufficiency: a controlled double-blind trial. Am J Kidney Dis 27:489–495

    Article  CAS  Google Scholar 

  21. Hou FF, Zhang X, Zhang GH, **e D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Gang RW (2006) Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Eng J Med 354:131–140

    Article  CAS  Google Scholar 

  22. Shahinfar S, Cano F, Sofffer BA, Ahmed T, Santoro EP, Zhang Z, Gleim G, Miller K, Vogt B, Blumer J, Biezogounov J (2005) A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens 18:183–190

    Article  CAS  Google Scholar 

  23. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH (2005) Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 68:1190–1198

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, Kidney Transplantation and Arterial Hypertension, The Children’s Memorial Health Institute, Aleja Dzieci Polskich 20, 04736, Warsaw, Poland

    Mieczysław Litwin, Ryszard Grenda, Joanna Śladowska & Jolanta Antoniewicz

Authors
  1. Mieczysław Litwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryszard Grenda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joanna Śladowska
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jolanta Antoniewicz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mieczysław Litwin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Litwin, M., Grenda, R., Śladowska, J. et al. Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors. Pediatr Nephrol 21, 1716–1722 (2006). https://doi.org/10.1007/s00467-006-0223-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-006-0223-2

Keywords

Search

Navigation